Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Subgroup analysis update for the ARROW study: once-weekly carfilzomib for R/R myeloma

Here, Keith Stewart, MB, ChB, of the Mayo Clinic, Rochester, MN, gives us an update on the subgroup analysis data for the ARROW study (NCT02412878), which compared a once-weekly vs. twice-weekly regimen of carfilzomib in combination with dexamethasone for relapsed/refractory multiple myeloma. This video was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.